UCB SA UNSP/ADR (UCBJY)
UCBJY moved a median of +0.00% 30 minutes after news, and 0.00% by the close. How UCBJY actually reacts to news — the realized, point-in-time move the market made, measured across 85 labeled events over the last three years with zero look-ahead.
UCBJY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 17% | 75 |
| 30-min | +0.00% | 51% | 77 |
| 60-min | 0.00% | 48% | 81 |
| to close | 0.00% | 49% | 85 |
| Middle 50% of UCBJY reactions | -0.21% to +0.30% |
|---|---|
| Median reaction (30-min) | +0.00% |
| Measured reactions | 85 |
Half of all UCB SA UNSP/ADR news events land between -0.21% and +0.30% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when UCBJY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to UCBJY's baseline. Nothing else.
Recent UCBJY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis | Press release | PR Newswire | -0.21% | -0.43% | |
| UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis | Press release | PR Newswire | +0.00% | -2.52% | |
| UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia | Press release | PR Newswire | — | +0.00% | |
| UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG | Press release | PR Newswire | +0.32% | -1.07% | |
| UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS) | Press release | PR Newswire | -0.10% | -0.06% | |
| UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing | Press release | PR Newswire | -0.51% | -1.41% | |
| Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award | Press release | PR Newswire | +0.01% | +0.23% | |
| Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome | Press release | PR Newswire | -0.08% | -0.54% | |
| UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S. | Press release | PR Newswire | -0.14% | +0.20% | |
| UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d) | Press release | PR Newswire | -0.09% | -0.39% | |
| UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members | Press release | PR Newswire | +0.01% | +0.68% | |
| BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data | Press release | PR Newswire | +0.04% | +0.00% | |
| Myasthenia Gravis Foundation of America Launches MGFA Food Support Program to Advance Nutrition Access and Health Equity for Individuals with Myasthenia Gravis | Press release | PR Newswire | +0.05% | +1.59% | |
| UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science | Press release | PR Newswire | — | +0.17% | |
| UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting | Press release | PR Newswire | -0.03% | -1.61% | |
| UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting | Press release | PR Newswire | +0.00% | +0.73% | |
| UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa | Press release | PR Newswire | +0.00% | +1.45% | |
| UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis | Press release | PR Newswire | +0.00% | +1.45% | |
| UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs | Press release | PR Newswire | +0.00% | +0.77% | |
| BIMZELX®?(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50 | Press release | PR Newswire | +0.00% | -2.62% | |
| Sixth Annual Seizure Action Plan Awareness Week to Promote Seizure Preparedness Nationwide, Feb. 9-16, 2026 | Press release | PR Web | -0.03% | +0.24% | |
| UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder | Press release | PR Newswire | +0.00% | -0.29% | |
| UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting | Press release | PR Newswire | +0.22% | -0.54% | |
| U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) | Press release | PR Newswire | +0.02% | -0.18% | |
| UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™ | Press release | PR Newswire | — | -0.42% | |
| UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session | Press release | PR Newswire | +0.10% | -0.54% | |
| BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis | Press release | PR Newswire | +0.00% | +1.12% | |
| Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) | Press release | PR Newswire | +0.00% | +0.52% | |
| BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years | Press release | PR Newswire | +0.00% | -0.73% | |
| BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints | Press release | PR Newswire | +0.00% | -0.73% | |
| Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care | Press release | PR Newswire | +0.00% | -0.70% | |
| UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress | Press release | Canada Newswire | +0.00% | +0.48% | |
| UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment | Press release | PR Newswire | +0.08% | +0.49% | |
| UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community | Press release | PR Newswire | +0.00% | -0.10% | |
| UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder | Press release | PR Newswire | +0.00% | -0.96% | |
| UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference | Press release | PR Newswire | +0.00% | -0.55% | |
| Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S. | Press release | PR Newswire | +0.00% | -1.78% | |
| UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity | Press release | PR Newswire | +0.00% | -0.49% | |
| BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis | Press release | PR Newswire | — | -0.26% | |
| UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences | Press release | PR Newswire | — | +0.33% | |
| UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025 | Press release | PR Newswire | -0.01% | -1.43% | |
| New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference | Press release | PR Newswire | +0.00% | -0.17% | |
| Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome | Press release | PR Newswire | — | +0.01% | |
| BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis | Press release | PR Newswire | +0.00% | +0.66% | |
| BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden | Press release | PR Newswire | +0.00% | +0.66% | |
| On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth | Press release | PR Newswire | +0.00% | +1.31% | |
| UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx) | Press release | PR Newswire | +0.00% | -0.31% | |
| UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting | Press release | PR Newswire | — | -0.45% | |
| UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting | Press release | PR Newswire | +0.00% | -0.64% | |
| UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa | Press release | PR Newswire | -0.02% | +0.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the UCBJY section they belong to.
Where else UCBJY is measured.
UCBJY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kane Biotech Inc (KNE_CDNX) | 85 | 0.00% | 22% |
| Regen Biopharma, Inc. Common (RGBP) | 85 | 0.00% | 36% |
| NUO THERAPEUTICS INC NEW (AURX) | 84 | 0.00% | 24% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 84 | 0.00% | 14% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is UCB SA UNSP/ADR's median reaction calculated?
Every labeled UCBJY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 85 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of UCBJY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does UCBJY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.